Form 4: Catalyst Pharmaceuticals Director David S. Tierney Reports Stock Sale

Director David S. Tierney of Catalyst Pharmaceuticals, Inc. reports the sale of 15,000 shares of common stock on August 21, 2024.

Summary

• On August 21, 2024, David S. Tierney, a director of Catalyst Pharmaceuticals, Inc., sold 15,000 shares of common stock.
• The sale was executed on the open market at a weighted average price of $20.097 per share, with individual sales ranging from $20.00 to $20.485.
• Tierney also exercised options to purchase 15,000 shares of common stock at a price of $4.01 per share.
• Following these transactions, Tierney directly owns 348,874 shares of Catalyst Pharmaceuticals.
• Tierney also owns options to purchase 188,931 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by a director. The director states the sale was for personal reasons and not due to disagreement with the company.

Management Comments

• Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry. Investors often monitor these filings for insights into management's perspective on the company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common metric followed across the pharmaceutical industry.
• Comparing Tierney's transactions to those of insiders at similar-sized companies like BioCryst Pharmaceuticals or Amicus Therapeutics could provide context.
• However, without knowing the specific reasons for the sale, it's difficult to draw definitive conclusions.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, depending on how the market interprets the transaction.

Key Dates